Sun Pharma to license key Escitalopram® patent applications to Lundbeck®

17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685 Registered Office : SPARC, Tandalja, Vadodara – 390 020. India Corporate Office : Acme Plaza, Andheri – Kurla Road, Andheri (East), Mumbai – 400 059. India FOR IMMEDIATE RELEASE Sun Pharma to License Key Escitalopram Patent Applications to Lundbeck To receive upfront payment and royalties Mumbai, July 10, 2009: Sun Pharmaceutical Industries Ltd. (“Sun Pharma”, collectively with its 100% subsidiary) announced that along with Caraco Pharmaceutical Laboratories, Ltd (“Caraco”), it had entered into agreements with Forest Laboratories, Inc., Forest Laboratories Holdings , Ltd., and H. Lundbeck A/S (collectively, “Forest”) to settle the legal proceedings related to Lexapro® (escitalopram oxalate) tablets. Among other things, with respect to Sun Pharma and Caraco, the agreement contains the following provisions: 1. Sun Pharma will license to Lundbeck on a worldwide basis certain patent applications related to the synthesis of escitalopram and citalo pram in exchange for an upfront payment and, if the technology is used, royalties on sales. 2. Forest will provide licenses to Caraco for any patents related to Lexapro® and with respect to the marketing of Caraco’s generic version of the product as of the date that any third party generic that has received final approval from the FDA enters the market other than an authorized generic or the first filer with Hatch-Waxman related exclusivity. 3. Caraco will take over the commercialization and sale of several products from Forest's Inwood business. Caraco will pay Forest an undisclosed advance agai nst royalties and royalties on net sales of these products. 4. Forest will reimburse Caraco for a portion of their costs related to this litigation. These agreements will be subject to review by the U.S. Federal Trade Commission. About Sun Pharmaceutical Industries Ltd. Established in 1983, listed since 1994 and headquartered in Indi a, Sun Pharmaceutical Indust ries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an intern ational, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulat ions as branded generics as well as generics in India, US and several other markets across the world. In India, the compan y is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastro enterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com. Contacts Uday Baldota Mira Desai Tel +91 22 6645 5645, Xtn 605 Tel +91 22 6645 5645, Xtn 606 Tel Direct +91 22 66455605 Tel Direct +91 22 66455606 Mobile +91 98670 10529 Mobile +91 98219 23797 E mail [email protected] E mail [email protected]

The release as fetched from its publisher. sunpharma.com ↗